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Figure 1a- Patient Flow 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Data for suspected DVT or PE are taken from site screening logs and are therefore only estimates of the total number with DVT 
or PE. 
 
 
393 (40%, 393/993) patients 
fulfilled trial eligibility criteria  
281 (72%, 281/393) committed to baseline 
research clinic, consented and randomised  
112 (28%, 112/393) did not commit to 
baseline research clinic 
993 (73%, 993/1361) accepted 
invitation to participate and 
consented to GP screening of 
eligibility  
101 (10%, 101/993) incomplete GP eligibility 
check  
499 (50%, 499/993) ineligible following GP 
eligibility screen  
Reason for ineligibility: 
110 (22%) no reason reported  
100 (20%) no longer receiving AT 
76 (15%) long term AT 
70 (14%) provoked DVT/PE 
46 (9%) distal/another site DVT 
39 (8%) recurrent DVTPE 
23 (5%) GP discretion 
16 (3%) high bleeding risk 
10 (2%) housebound 
8 (2%) active cancer 
1 (0.2%) pregnancy 
 
368 (27%, 368/1361) declined invitation 
to participate  
1361 potentially eligible 
patients responded to the 
invitation 
3388 potentially eligible 
patients provided with an 
invitation to participate 
2027 (60%, 2027/3388) No response to 
invitation  
Screening of 8422* patients 
with suspected DVT or PE 
attending the recruitment site  
5034 Excluded following 
screening 
 Figure 1b- Patient Flow following randomisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Includes 4 participants who withdrew consent to use their data 
** Includes 1 participant who withdrew consent to use their data 
*** Includes 2 patients receiving rivaroxaban therapy 
 
N=134 
Data available for analysis of primary outcome 
(time to the first recurrent venous 
thromboembolism since randomisation up to 
24 months follow up) 
Excluded from analysis (N=6) 
 Consent to use data withdrawn (N=4) 
 Participant with antiphospholipid 
syndrome (N=0)  
 Participant with protein C and/or protein S 
or antithrombin deficiency (N=2) 
 
Randomised 
N=281 
Discontinued anticoagulation 
therapy (AT) 
N=140 
Extended anticoagulation therapy  
(AT) 
N=141 
Withdrawn (N=6)* Withdrawn 
(N=2)** 
N=139*** 
Data available for analysis of primary 
outcome (time to the first recurrent venous 
thromboembolism since randomisation up 
to 24 months follow up) 
Excluded from analysis (N=2) 
 Consent to use data withdrawn (N=1) 
 Participant with antiphospholipid    
syndrome (N=1) 
 Participant with protein C and/or protein 
S or antithrombin deficiency (N=0) 
 
 
Table 1- Baseline Characteristics 
  
Characteristic 
Discontinued AT 
N=134 
Extended AT 
N=139 
Total 
N=273 
Age at time of randomisation 
  
  Mean (SD) 63.3 (12.7) 62.2 (13.0) 62.7 (12.8) 
  Median (IQR) 64.5 (55.6-74.0) 64.4 (53.3-72.4) 64.4 (54.4-72.7) 
Sex, n (%) 
   
  Female 44 (32.8) 45 (32.4) 89 (32.6) 
  Male 90 (67.2) 94 (67.6) 184 (67.4) 
Diagnosis (DVT/PE)1, n (%)    
  Unprovoked DVT 69 (51.5) 70 (50.4) 139 (50.9) 
  Unprovoked PE 65 (48.5) 69 (49.6) 134 (49.1) 
Ethnicity, n (%) 
   
  White 131 (97.8) 131 (94.2) 262 (96.0) 
  Mixed 1 (0.8) 0 (0.0) 1 (0.4) 
  Asian or Asian British 0 (0.0) 3 (2.2) 3 (1.1) 
  Black or Black British 2 (1.5) 5 (3.6) 7 (2.6) 
  Other ethnic groups 0 (0.0) 0 (0.0) 0 (0.0) 
Smoking status, n (%) 
 
    
  Non-smoker 63 (47.0) 60 (43.2) 123 (45.1) 
  Ex-smoker 48 (35.8) 60 (43.2) 108 (39.6) 
  Current smoker 19 (14.2) 18 (13.0) 37 (13.6) 
  Smokes occasionally 4 (3.0) 1 (0.7) 5 (1.8) 
Alcohol consumption, n (%)   
  No 44 (32.8) 51 (36.7) 95 (34.8) 
  Yes 90 (67.2) 88 (63.3) 178 (65.2) 
BMI classification, n (%) 
   
  Underweight (<18.5) 2 (1.5) 0 (0.0) 2 (0.7) 
  Normal range (18.5-24.99) 47 (35.1) 47 (33.8) 94 (34.4) 
  Overweight (25-29.99) 51 (38.1) 53 (38.1) 104 (38.1) 
  Obese (≥30) 33 (24.6) 37 (26.6) 70 (25.6) 
  Missing 1 (0.8) 2 (1.4) 3 (1.1) 
Family history of VTE, n (%)     
  No 102 (76.1) 102 (73.4) 204 (74.7) 
  Yes 32 (23.9) 37 (26.6) 69 (25.3) 
Previous medical history    
Stroke, n (%)    
  No 130 (97.0) 136 (97.8) 266 (97.4) 
  Yes 4 (3.0) 3 (2.2) 7 (2.6) 
Transient Ischaemic Attack (TIA), 
n (%)    
  No 129 (96.3) 138 (99.3) 267 (97.8) 
  Yes 5 (3.7) 1 (0.7) 6 (2.2) 
Angina, n (%)    
  No 129 (96.3) 136 (97.8) 265 (97.1) 
  Yes 5 (3.7) 3 (2.2) 8 (2.9) 
Myocardial Infarction (MI), n (%)    
  No 133 (99.3) 134 (96.4) 267 (97.8) 
  Yes 1 (0.8) 5 (3.6) 6 (2.2) 
Ischaemic Heart Disease (IHD), n 
(%) 
   
  No 130 (97.0) 136 (97.8) 266 (97.4) 
  Yes 4 (3.0) 3 (2.2) 7 (2.6) 
Peripheral Vascular Disease 
(PVD), n (%) 
   
  No 134 (100.0) 134 (96.4) 268 (98.2) 
  Yes 0 (0.0) 5 (3.6) 5 (1.8) 
PTS score (categorical), n (%) 
   
  No PTS 70 (52.2) 66 (47.5) 136 (49.8) 
  Mild PTS 42 (31.3) 51 (36.7) 93 (34.1) 
  Moderate PTS 15 (11.2) 18 (13.0) 33 (12.1) 
  Severe PTS 5 (3.7) 2 (1.4) 7 (2.6) 
  Missing 2 (1.5) 2 (1.4) 4 (1.5) 
PTS score    
  Mean (SD) 5.2 (4.2) 5.1 (3.8) 5.2 (4.0) 
  Median (IQR) 4.0 (2.0-7.5) 5.0 (2.0-8.0) 4.0 (2.0-8.0) 
  Missing 2 2 4 
EQ-5D-3L    
  Mean (SD) 0.8 (0.2) 0.8 (0.3) 0.8 (0.3) 
  Median (IQR) 0.8 (0.7-1.0) 0.8 (0.7-1.0) 0.8 (0.7-1.0) 
  Missing 0 4 4 
VEINES-QOL score    
  Mean (SD) 48.2 (10.7) 49.6 (9.9) 48.9 (10.3) 
  Median (IQR) 51.1 (41.1-57.6) 53.0 (44.6-56.7) 52.1 (43.3-57.5) 
  Missing 0 2 2 
Health care utilisation due to PTS    
Patient receiving primary care  
treatment, n (%) 
   
  No 124 (92.5) 128 (92.1) 252 (92.3) 
  Yes 9 (6.7) 11 (7.9) 20 (7.3) 
  Missing 1 (0.8) 0 (0.0) 1 (0.4) 
Type of nurse patients were  
seen by, n (%)    
  Practice 2 (1.5) 1 (0.7) 3 (1.1) 
  District 0 (0.0) 0 (0.0) 0 (0.0) 
  HCA 0 (0.0) 0 (0.0) 0 (0.0) 
 None 59 (44.0) 70 (50.4) 129 (47.3) 
 Other 0 (0.0) 0 (0.0) 0 (0.0) 
 Missing 73 (54.5) 68 (48.9) 141 (51.7) 
Patient receiving treatment for a 
leg ulcer, n (%) 
   
  No 66 (49.3) 71 (51.1) 137 (50.2) 
  Yes 1 (0.8) 2 (1.4) 3 (1.1) 
  Missing 67 (50.0) 66 (47.5) 133 (48.7) 
Patient receiving secondary care 
treatment, n (%) 
   
  No 131 (97.8) 135 (97.1) 266 (97.4) 
  Yes 1 (0.8) 4 (2.9) 5 (1.8) 
  Missing 2 (1.5) 0 (0.0) 2 (0.7) 
1minimisation variable 
 
 
 
